Matinas BioPharma MTNB Stock
Matinas BioPharma Price Chart
Matinas BioPharma MTNB Financial and Trading Overview
| Matinas BioPharma stock price | 0.65 USD |
| Previous Close | 0.6 USD |
| Open | 0.6 USD |
| Bid | 0 USD x 310000 |
| Ask | 0 USD x 10000 |
| Day's Range | 0.62 - 0.67 USD |
| 52 Week Range | 0.48 - 3.09 USD |
| Volume | 26.37K USD |
| Avg. Volume | 151.03K USD |
| Market Cap | 4.04M USD |
| Beta (5Y Monthly) | 1.681 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.97 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
MTNB Valuation Measures
| Enterprise Value | 2.83M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.21033333 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.3368644 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.409 |
Trading Information
Matinas BioPharma Stock Price History
| Beta (5Y Monthly) | 1.681 |
| 52-Week Change | -30.35% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 3.09 USD |
| 52 Week Low | 0.48 USD |
| 50-Day Moving Average | 0.66 USD |
| 200-Day Moving Average | 0.92 USD |
MTNB Share Statistics
| Avg. Volume (3 month) | 151.03K USD |
| Avg. Daily Volume (10-Days) | 65.74K USD |
| Shares Outstanding | 6.41M |
| Float | 5.23M |
| Short Ratio | 0.2 |
| % Held by Insiders | 22.11% |
| % Held by Institutions | 5.68% |
| Shares Short | 68.9K |
| Short % of Float | 1.08% |
| Short % of Shares Outstanding | 1.08% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:50 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -48.50% |
| Return on Equity (ttm) | -228.36% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 0 USD |
| EBITDA | -6924000 USD |
| Net Income Avi to Common (ttm) | -11228000 USD |
| Diluted EPS (ttm) | -1.97 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.4M USD |
| Total Cash Per Share (mrq) | 0.37 USD |
| Total Debt (mrq) | 1.19M USD |
| Total Debt/Equity (mrq) | 39.35 USD |
| Current Ratio (mrq) | 1.324 |
| Book Value Per Share (mrq) | 0.472 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -6605000 USD |
| Levered Free Cash Flow (ttm) | -2970375 USD |
Profile of Matinas BioPharma
| Country | United States |
| State | NJ |
| City | Bedminster |
| Address | 1545 Route 206 South |
| ZIP | 07921 |
| Phone | 908 484 8805 |
| Website | https://www.matinasbiopharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 2 |
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Q&A For Matinas BioPharma Stock
What is a current MTNB stock price?
Matinas BioPharma MTNB stock price today per share is 0.65 USD.
How to purchase Matinas BioPharma stock?
You can buy MTNB shares on the NYSE American exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Matinas BioPharma?
The stock symbol or ticker of Matinas BioPharma is MTNB.
Which industry does the Matinas BioPharma company belong to?
The Matinas BioPharma industry is Biotechnology.
How many shares does Matinas BioPharma have in circulation?
The max supply of Matinas BioPharma shares is 6.41M.
What is Matinas BioPharma Price to Earnings Ratio (PE Ratio)?
Matinas BioPharma PE Ratio is now.
What was Matinas BioPharma earnings per share over the trailing 12 months (TTM)?
Matinas BioPharma EPS is -1.97 USD over the trailing 12 months.
Which sector does the Matinas BioPharma company belong to?
The Matinas BioPharma sector is Healthcare.